- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Sustainable Track Record
Hong Kong Pharmaceuticals & Biotech Sustainable Track Record
Results
3
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
3 companies
Consun Pharmaceutical Group
Market Cap: HK$13.0b
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
1681
HK$15.40
7D
-0.2%
1Y
84.0%
HBM Holdings
Market Cap: HK$11.1b
A biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally.
2142
HK$13.24
7D
2.2%
1Y
926.4%
Shanghai Henlius Biotech
Market Cap: HK$38.0b
Engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.
2696
HK$69.85
7D
-4.3%
1Y
220.4%